With the current Article 50 extension deadline of 31 October 2019 looming against a complex and uncertain political backdrop, and talks between the UK and EU continuing without any clear sign of a definitive outcome, the possibility of a no-deal Brexit remains at an all-time high.
This report highlights the specific risk implications of a no-deal Brexit scenario, the preparations undertaken thus far to protect industry stakeholders and the commitment and investment made by the government to ensure that the UK retains its status as a world leader in science, innovation and healthcare.
- Brexit White Paper: protecting the UK life sciences industry
- House of Commons publishes report on the impact of Brexit on the pharmaceutical sector
- House of Commons considers the impact of Brexit on the life sciences sector
- Implications of ‘No Deal’ for the medical devices industry post-Brexit
- Brexit page